These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

684 related articles for article (PubMed ID: 29147032)

  • 41. Gene therapy for lysosomal storage disorders.
    Barranger JM; Novelli EA
    Expert Opin Biol Ther; 2001 Sep; 1(5):857-67. PubMed ID: 11728220
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Enzyme replacement therapy and substrate reduction therapy in lysosomal storage disorders with neurological expression.
    Valayannopoulos V
    Handb Clin Neurol; 2013; 113():1851-7. PubMed ID: 23622408
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evolving therapies in neuronopathic LSDs: opportunities and challenges.
    Rajan DS; Escolar ML
    Metab Brain Dis; 2022 Oct; 37(7):2245-2256. PubMed ID: 35442005
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The NCS-LSD cohort study: a description of the methods and analyses used to assess the long-term effectiveness of enzyme replacement therapy and substrate reduction therapy in patients with lysosomal storage disorders.
    Henley WE; Anderson LJ; Wyatt KM; Nikolaou V; Anderson R; Logan S
    J Inherit Metab Dis; 2014 Nov; 37(6):939-44. PubMed ID: 24519353
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Drug Repurposing and Lysosomal Storage Disorders: A Trick to Treat.
    Hay Mele B; Rossetti F; Cubellis MV; Monticelli M; Andreotti G
    Genes (Basel); 2024 Feb; 15(3):. PubMed ID: 38540351
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Polymer-based drug delivery systems under investigation for enzyme replacement and other therapies of lysosomal storage disorders.
    Placci M; Giannotti MI; Muro S
    Adv Drug Deliv Rev; 2023 Jun; 197():114683. PubMed ID: 36657645
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immune response to enzyme replacement therapies in lysosomal storage diseases and the role of immune tolerance induction.
    Kishnani PS; Dickson PI; Muldowney L; Lee JJ; Rosenberg A; Abichandani R; Bluestone JA; Burton BK; Dewey M; Freitas A; Gavin D; Griebel D; Hogan M; Holland S; Tanpaiboon P; Turka LA; Utz JJ; Wang YM; Whitley CB; Kazi ZB; Pariser AR
    Mol Genet Metab; 2016 Feb; 117(2):66-83. PubMed ID: 26597321
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Delivery of recombinant proteins via the cerebrospinal fluid as a therapy option for neurodegenerative lysosomal storage diseases.
    Hemsley KM; Hopwood JJ
    Int J Clin Pharmacol Ther; 2009; 47 Suppl 1():S118-23. PubMed ID: 20040322
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Enzyme replacement therapy and beyond-in memoriam Roscoe O. Brady, M.D. (1923-2016).
    Ries M
    J Inherit Metab Dis; 2017 May; 40(3):343-356. PubMed ID: 28314976
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Lysosomes and lysosomal storage diseases].
    Germain DP
    J Soc Biol; 2002; 196(2):127-34. PubMed ID: 12360741
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hematopoietic Stem Cell Gene Therapy for Storage Disease: Current and New Indications.
    Biffi A
    Mol Ther; 2017 May; 25(5):1155-1162. PubMed ID: 28389320
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Nanotechnology-based approaches for treating lysosomal storage disorders, a focus on Fabry disease.
    Abasolo I; Seras-Franzoso J; Moltó-Abad M; Díaz-Riascos V; Corchero JL; Pintos-Morell G; Schwartz S
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2021 May; 13(3):e1684. PubMed ID: 33314628
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Gene therapy for lysosomal storage diseases and peroxisomal diseases.
    Ohashi T
    J Hum Genet; 2019 Feb; 64(2):139-143. PubMed ID: 30498239
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Gene therapy approaches for lysosomal storage disease: next-generation treatment.
    Byrne BJ; Falk DJ; Clément N; Mah CS
    Hum Gene Ther; 2012 Aug; 23(8):808-15. PubMed ID: 22794786
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Potential Treatment of Lysosomal Storage Disease through Modulation of the Mitochondrial-Lysosomal Axis.
    Kuk MU; Lee YH; Kim JW; Hwang SY; Park JT; Park SC
    Cells; 2021 Feb; 10(2):. PubMed ID: 33671306
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Biomarkers for gene therapy clinical trials of lysosomal storage disorders.
    Rossi A; Malvagia S; la Marca G; Parenti G; Brunetti-Pierri N
    Mol Ther; 2024 Sep; 32(9):2930-2938. PubMed ID: 38850023
    [TBL] [Abstract][Full Text] [Related]  

  • 57. ER and oxidative stresses are common mediators of apoptosis in both neurodegenerative and non-neurodegenerative lysosomal storage disorders and are alleviated by chemical chaperones.
    Wei H; Kim SJ; Zhang Z; Tsai PC; Wisniewski KE; Mukherjee AB
    Hum Mol Genet; 2008 Feb; 17(4):469-77. PubMed ID: 17989065
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Sphingolipid lysosomal storage disorders.
    Platt FM
    Nature; 2014 Jun; 510(7503):68-75. PubMed ID: 24899306
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Gene therapy for the lysosomal storage disorders.
    Cabrera-Salazar MA; Novelli E; Barranger JA
    Curr Opin Mol Ther; 2002 Aug; 4(4):349-58. PubMed ID: 12222873
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Models to study basic and applied aspects of lysosomal storage disorders.
    Gaudioso Á; Silva TP; Ledesma MD
    Adv Drug Deliv Rev; 2022 Nov; 190():114532. PubMed ID: 36122863
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.